Johnson & Johnson (NYSE:JNJ) Shares Purchased by Sunpointe LLC

Sunpointe LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 251.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,298 shares of the company’s stock after acquiring an additional 10,941 shares during the quarter. Johnson & Johnson makes up 1.1% of Sunpointe LLC’s portfolio, making the stock its 24th biggest holding. Sunpointe LLC’s holdings in Johnson & Johnson were worth $2,212,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in JNJ. AMF Tjanstepension AB lifted its position in Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after buying an additional 52,997 shares during the period. Alpha Financial Partners LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $209,000. Wealth Group Ltd. acquired a new stake in Johnson & Johnson during the third quarter worth about $213,000. Swedbank AB raised its stake in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after acquiring an additional 111,570 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 8.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 87,476 shares of the company’s stock worth $14,176,000 after acquiring an additional 6,642 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $162.35 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market capitalization of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The stock has a fifty day moving average of $148.93 and a 200-day moving average of $155.86. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Bank of America lowered their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Finally, Guggenheim boosted their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.